lorlatinib
Pfizer Oncology Revenues Fall 4 Percent in Q2; Officials Highlight Encouraging Data From Trials
Executives said the firm's acquisition of Seagen and advancement of new breast cancer candidates will help refocus its efforts in oncology.
Pfizer saw revenue declines in several oncology products, including the CDK4/6 inhibitor Ibrance, the ALK inhibitor Xalkori, and the BRAF inhibitor Braftovi.
The firm's newer precision oncology drugs, including Lorbrena, Braftovi, and Mektovi, however, continued their sales growth in Q3.
Pfizer Reports Q2 US Sales Growth for Ibrance Despite Declines in Other Markets, Greater Competition
Premium
Pfizer executives said the drug saw US sales growth for the first time since Q4 2020, despite more patients continuing to access the drug through its assistance program.
Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications
The Strata PATH trial is exploring new precision oncology indications for already marketed drugs, including for four Pfizer treatments.